

Review

Transcriptional activation of nuclear estrogen receptor and progesterone receptor and its regulation

XIN Qi-Liang^{1,2,#}, QIU Jing-Tao^{1,2,#}, CUI Sheng¹, XIA Guo-Liang¹, WANG Hai-Bin^{2,*}

¹State Key Laboratory for Agro-biotechnology, College of Biological Sciences, China Agricultural University, Beijing 100193, China;

²State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China

Abstract: Estrogen receptor (ER) and progesterone receptor (PR) are two important members of steroid receptors family, an evolutionarily conserved family of transcription factors. Upon binding to their ligands, ER and PR enter cell nucleus to interact with specific DNA element in the context of chromatin to initiate the transcription of diverse target genes, which largely depends on the timely recruitment of a wide range of cofactors. Moreover, the interactions between steroid hormones and their respective receptors also trigger post-translational modifications on these receptors to fine-tune their transcriptional activities. Besides the well-known phosphorylation modifications on tyrosine and serine/threonine residues, recent studies have identified several other covalent modifications, such as ubiquitylation and sumoylation. These post-translational modifications of steroid receptors affect its stability, subcellular localization, and/or cofactor recruitment; eventually influence the duration and extent of transcriptional activation. This review is to focus on the recent research progress on the transcriptional activation of nuclear ER and PR as well as their physiological functions in early pregnancy, which may help us to better understand related female reproductive diseases.

Key words: estrogen receptor; progesterone receptor; post-translational modifications; transcriptional activation; cofactors; early pregnancy

雌、孕激素受体的转录激活与调控

辛启亮^{1,2,#}, 邱静涛^{1,2,#}, 崔胜¹, 夏国良¹, 王海滨^{2,*}

¹中国农业大学生物学院, 农业生物技术国家重点实验室, 北京 100193; ²中国科学院动物研究所, 干细胞与生殖生物学国家重点实验室, 北京 100101

摘要: 雌激素受体与孕激素受体都是类固醇激素受体这一进化上高度保守的转录因子家族的重要成员。当雌、孕激素受体分别与其配体在细胞浆中结合后进入核内, 与靶基因上特异的DNA响应元件结合, 并适时募集一些辅助转录因子, 诱导特定基因转录表达, 影响靶细胞的功能活动。雌、孕激素受体的转录活性还因其在蛋白翻译后所发生的不同修饰而改变。蛋白翻译后的修饰种类繁多。经典的修饰为丝/苏氨酸和酪氨酸残基的磷酸化修饰。近些年的研究发现, 泛素化与类泛素化修饰对激素受体的稳定性、在亚细胞定位及其对辅助因子的募集等方面都发挥重要作用, 并最终影响激素受体的转录活性。本文旨在对国内外近几年关于雌、孕激素受体的转录活性调控及其在早期妊娠中的生理意义进行综述, 这将有助于理解雌、孕激素作用异常相关的女性生殖疾病。

关键词: 雌激素受体; 孕激素受体; 翻译后修饰; 转录激活; 共辅助因子; 早期妊娠

中图分类号: Q492; R339.2

Received 2016-02-02 Accepted 2016-06-08

[#]These authors contributed equally to this review.

^{*}Corresponding author. Tel: +86-10-64807868; E-mail: haibin.wang@vip.163.com

1 Introduction

Dynamic coordination of gene networks involved in numerous physiological, developmental, and metabolic processes can be ascribed in a large part to a superfamily of ligand-activated transcription factors, the steroid receptors^[1] including the androgen receptor (AR), estrogen receptor (ER), glucocorticoid receptor (GR), mineralocorticoid receptor (MR) and progesterone receptor (PR), which can induce or repress gene expression by binding to the respective response elements in chromatin^[2]. ER, existing in two isoforms ER α and ER β derived from distinct genes, mainly mediates the action of estrogens in ER-expressing tissues such as the mammary gland and the reproductive tract^[3]. With respect to the PR, there are two main isoforms PR-A and PR-B that are derived from the same gene and mediate the actions of progestins in various pregnancy events as well as sexual behavior^[4].

A generally accepted framework for nuclear receptor activation including the steroid receptor is that ligand-bound receptors via forming homodimers bind to hormone response elements located within the upstream promoter/enhancer sequences of target genes followed with recruitment of co-activating proteins, and eventually activate gene transcription^[5]. In this respect, steroid receptors possess an evolutionarily conserved domain structure, which consists of DNA-binding domain responsible for the recognition of a specific DNA motif encoded in the genome, ligand-binding domain, and transactivation domains for transcription initiation^[6]. In the absence of ligands, steroid receptors stay in the cytoplasm, forming complexes with chaperone proteins. Molecular chaperones and co-chaperones are typically known to assist the correct conformation of steroid receptors for ligand binding^[7]. Following ligand binding, steroid receptors undergo conformational changes and translocate into the nucleus. The final outcome of steroid receptor activation is to modulate the transcription activity of target genes through recruiting general transcription factors and RNA polymerase II^[8]. Although it is known that steroid receptors can interact directly with general transcription factors, there is overwhelming evidence that ligand-bound receptors need recruit co-regulators that modulate the transcriptional activities^[1,9]. Moreover, post-translational modification of ligand-bound steroid receptors is an important regulator loop for their functional activation. These covalent changes have shown to affect

receptor stability, subcellular localization as well as the interactions with other proteins^[10], pointing toward the complexity of ligand-receptor activation. In this review, we summarize recent research progress on transcriptional activation machinery of ER and PR, as well as their pathophysiological significance in various reproductive events.

2 Structures of ER and PR

2.1 ER

ER α and ER β isoforms are encoded by two distinct genes in both mice and humans^[11]. ER α is predominantly expressed in mammary glands, pituitary, hypothalamus, ovarian theca cells and reproductive tract. In contrast, ER β is primarily expressed in ovarian granulosa cells, lung and prostate^[3]. Transcription of the mouse ER α gene *in vivo* predominantly results in a single transcript of approximately 6.3 kb transcribed from 9 exons. This transcript encodes a protein of 599 amino acids with an approximate molecular mass of 66 kDa^[12]. Human ER α consists of 595 amino acids and exhibits a similar molecular mass as mouse ER α ^[13,14]. While human ER α gene has been mapped to chromosome 6^[15], mouse ER α gene is located on chromosome 10^[16]. The existence of multiple promoter and regulatory regions in the 5'-untranslated sequences of the human and rat ER α has been described, but only a single open reading frame appears to exist^[17,18]. Previous studies indicated that the rodent ER β was composed of 485 amino acids with an estimated molecular mass of 54 kDa and therefore was slightly smaller than the ER α ^[11,19]. The majority of this difference in size between two ER isoforms was due to a significantly shorter N9 terminus in ER β protein^[20].

Similarly to most other nuclear receptors, ERs contain a domain with ligand-independent activation function (AF-1) at the N-terminus, a DNA-binding domain (DBD domain) followed by a hinge domain, and a ligand-binding/dimerization domain (LBD) at the C-terminus that contains a ligand-dependent transcription activation domain (AF-2)^[21] (Fig. 1).

2.2 PR

Human PRs are encoded by a single gene located on chromosome 11 (11q22-q23). Expression of PR isoforms is controlled by two promoters to produce two major mRNA transcripts that encode two proteins: the full-length PR-B (116 kDa) that is controlled by the




Fig. 1. Domain structures of estrogen receptor (ER). Diagram of translational start sites for human ER α and ER β isoforms. ER is a modular protein consisting of a number of functional domains including the NTD (amino-terminal domain), DBD (DNA binding domain), H (hinge region), and LBD (ligand binding domain) as indicated. The presence of these domains and the activation function domains (AF-1, AF-2) allow for the unique function of the individual EGR isoforms. METc, methionine.

distal PR-B promoter region and initiated from the first AUG translational start codon, and PR-A (94 kDa) that is controlled by the proximal PR-A promoter region and initiated from the second AUG translational start codon that is 492 bases from the PR-A start codon^[22]. Other PR isoforms are thought to be generated by the initiation of translation from further downstream AUG start sites (e.g. PR-C), exon splicing or exon insertions, respectively^[22], but their physiologic relevance is uncertain.

Like the ER protein, both PR isoforms consist of multiple domains, such as the AF-1 in the N-terminus, the DBD and the ligand binding domain which contains AF-2. The PR-B isoform has an additional 164 amino acids in the N-terminus which contains an additional activation domain (AF-3) (Fig. 2)^[23]. This region has been shown to endow a transactivation function that is specific to the PR-B protein, and plays an essential role in specifying target genes activated only by PR-B but not by PR-A^[24, 25]. In fact, during embryo implantation and decidualization, evidence from genetic mouse models and *in vitro* manipulation of human uterine cells has demonstrated while PR-A is the main functional isoform in mice, PR-B is the functional one in humans, although both isoforms are simultaneously expressed in mouse uteri as well as in human endometrium^[26, 27]. These findings suggest that PR-A and PR-B can differentially regulate the expression of targeting




Fig. 2. Progesterone receptor isoforms. Diagram of translational start sites for human PR-A, PR-B, and PR-C isoforms. The numbers of the amino acids found at the boundaries in the individual receptors between the NTD (amino-terminal domain), DBD (DNA binding domain), H (hinge region), and LBD (ligand binding domain) are indicated. The presence of these domains and the activation domains (AF-1, AF-2, and AF-3) allow for the unique function of the individual PR isoforms. METc, methionine.

genes in response to progesterone, involving different transactivation capabilities in different targeting tissues^[28, 29].

3 Transcriptional activation of ER and PR

3.1 ER activation

Estrogen may activate or repress the transcription of ER-targeting genes potentially by recruiting distinct classes of co-regulators that have chromatin remodeling properties. Structural and functional studies revealed that ER co-activators are recruited to estrogen-responsive genes through their interaction with activated receptors. In turn, the co-activator complex remodels the chromatin at this region through histone modification, facilitating RNA polymerase II-mediated transcription^[30, 31]. With respect to the repressed genes, it has also been established that estrogen stimulates the selective association of ER with co-repressors^[32, 33]. The interaction of these co-repressors prompts the binding of chromatin deacetylases and other repressive modification enzymes, therefore leading to transcriptional inhibition.

Like all other members of the nuclear receptor family, ERs can be activated upon ligand binding^[34]. Importantly, ER-mediated transactivation can reach its maxi-

mal level only if ER is phosphorylated at various sites, even in the absence of estrogen binding (Fig. 3). The ER proteins are generally believed to shuttle between the cytoplasm and nucleus. *In vitro* experiments have demonstrated that ligand free ER α , like other steroid nuclear receptors, is maintained in a non-DNA binding form encompassed by a multi-chaperone complex organized around HSP90^[35]. However, little information is available with regard to ER β . Upon ligand binding, ER α undergoes conformational changes that control its interaction with heat shock proteins and co-regulators. These interactions determine ER binding to the 13-bp estrogen response element sequence (ERE) within the promoter. ER-dimers dynamically and sequentially recruit various regulatory protein complexes contributing to chromatin remodeling, thereby strongly enhancing transcriptional activity^[36]. Ligand-activation of ER may also stimulate the indirect binding of ER to DNA

by protein-protein interactions with transcription factors such as AP-1 or Sp-1, which anchor the pre-initiation complex to ERE^[37]. In addition, various ER variants may alter the estrogenic response. For example, ER α -36, an ER α variant lacking the N-terminal domain and a truncated ligand-binding C-terminal domain, has been implicated as a mediator of extra-nuclear (non-genomic) actions.

3.2 PR activation

Prior to the presence of progesterone in the extracellular space, the PR protein resides within the cytoplasm. In the absence of ligand, PRs reside in the cytoplasm, forming a complex with chaperone proteins. These chaperones hold the receptor in an inactive state, primed to bind to ligands. These proteins consist of heat shock protein HSP90, a P23 chaperone protein, and one of four chaperones containing a tetratricopeptide repeat (TPR) domain^[35]. The first step in this




Fig. 3. A model depicting some of the key steps of the canonical pathway of steroid receptors. Binding of the HSP90, P23 and a preassembled complex of Hop, HSP70 and HSP40 assists a mature folding of the steroid receptor (SR). Addition of HSP90-dimers and P23 complete the assembled complex, termed the “foldosome”. Release of Hop, HSP70 and HSP40 and addition of any one of the tetratricopeptide repeat (TPR)-containing cochaperone, for example FKBP52, which mediates translocation to the nucleus in a molecular complex was termed the “transportosome”. Within the nucleus FKBP52 is released and the receptor binds to the response elements as an active dimer. Other co-activators, such as NCOAs, E6AP, UBCH-7, P300, enhance the activity of the SR most likely by stabilizing the active state of the receptors. The molecular chaperones HSP90 and HSP70 possibly also play a role in this process. SHR: steroid hormone receptor.

assembly is the formation of a molecular complex (HSP90, PR, HSP70, HSP40), termed the foldosome (Fig. 3).

Jensen two-step hypothesis on cytoplasmic-nuclear transportation of steroid receptors upon activation, together with the finding that molecular chaperones and co-chaperones bind to non-liganded receptors, collectively supported the concept that molecular chaperones confine steroid receptors in an inactive cytoplasmic state^[38]. Upon ligand binding, PR undergoes a conformational change that triggers release from the chaperone complex and favors receptor dimerization. The receptor/chaperone complex is thought to move along the cytoskeleton to the nucleus in a format described as the transportosome^[39]. The affinity of the FKBP52-receptor complex for dynein possibly determines transportation of the steroid receptors into the nucleus, and further stabilizes the PR in a high affinity form^[40]. Dimerized hormone-receptor complexes translocate to the nucleus, where they bind to DNA and direct the recruitment of transcriptional co-activators, co-repressors, and the transcriptional machinery to modulate the expression of target genes^[41].

Once in the nucleus, the steroid receptor/molecular chaperone complex dissociates and the steroid receptor is converted into a DNA binding form^[41]. In the nucleus, molecular chaperones function as modulators of the DNA binding and transcriptional activities of steroid receptors^[42]. The use of the HSP90-specific inhibitor GA blocked the transcriptional activity of this receptor on chromatin, demonstrating a crucial role of HSP90 in the nuclear function of the PR^[42]. The DBD gives the receptor specificity for the target genes. This specificity is determined by which DNA sequences the DBD will recognize. These sequences or progesterone response elements (PREs) are located in enhancer/promoter regions of the target genes. This domain is responsible for linking the receptors to the cellular transcriptional machinery and regulates transcription of target genes.

Upon the binding of the receptor to the PRE, the activated receptor then interacts with co-activators, which will link the steroid hormone receptor to the basal transcriptional machinery of the cell. The co-activators not only link the receptor to the transcription machinery, but also facilitate transcription by covalently modifying chromatin. These co-activators have histone acetyltransferase (HAT) activity that functions to acetylate histone proteins, allowing the DNA to achieve a con-

formation that increases the accessibility of the target gene promoter to the activated receptor, and basal transcriptional machinery. This remodeling of the chromatin serves to facilitate the transcription of specific genes. These co-activators include members of the steroid receptor coactivator (SRC) family, CREB binding protein and related P300 protein (CBP/P300), high mobility group proteins (HMGs), and E3 ubiquitin protein ligases (E6AP and RPF-1). Thus, the entire process of steroid hormone receptor activation results in the enhanced transcription of specific target genes, as well as the degradation of the activated steroid hormone receptor^[43].

Upon binding ligand, dimerizing and entering into the nucleus, the nuclear receptor dimer binds to recognition sequences known as response elements. Nuclear receptor proteins have their own response elements, but at times, can cross-react with other response element^[44]. Although response elements for a particular nuclear receptor, such as the PR, have a specific sequence motif, there is room for flexibility within the sequence. The PREs usually consist of a palindromic hormone response element of AGAACAnnnTGTTCT^[45]. However, PR binding is not limited to the full PRE. Indeed, it was determined that PR can bind to promoters of known progesterone target genes such as *Lifr*, *Gata2*, *Cyp26a1*, and *Ihh* with just half the sequence of the normal PRE^[46]. Additionally, it was identified that PR can also bind to promoters of known target genes *Egfr* and *Wnt7a* with no canonical PRE present^[46] (Fig. 3).

Functional dissection of nuclear receptor co-regulators revealed that their transcriptional co-regulation was linked to histone acetylation. Histone modification and chromatin remodeling indicate that histone-modifying enzymes, including histone methylases and chromatin remodelers, are potential transcriptional co-regulators that interact directly and indirectly with nuclear receptors^[47, 48].

Chromatin remodeling is a fundamental process of chromatin reorganization^[49]. The chromatin state of a normal nucleosomal array is inhibitory for transcriptional events, but is convertible into an even more inactivated state (heterochromatin) by the action of packing nucleosomal arrays, which work through association with histone H1 and non-histone proteins. Conversely, the normal nucleosomal array can be loosened, exposing naked DNA in active chromatin states (euchromatin). Through a process termed histone-octamer sliding,

chromatin remodelers can induce the reversible organization of nucleosomal arrays without unwinding DNA^[50]. Chromatin remodeling appears to be indispensable for dynamic gene activation and repression, and hence, chromatin remodelers are assumed to globally co-regulate DNA-binding transcription factors, at least indirectly. Three types of ATP-dependent chromatin remodelers have been reported to facilitate transcriptional events. Switch/Sucrose non-fermenting (SWI/SNF)-type and imitation switch (ISWI)-type complexes are known to participate in both transcription activation and repression^[51].

PR-mediated transcriptional regulation is exerted through cyclical recruitment and dismissal of multiple co-regulator complexes with distinct enzymatic activities, including HATs, histone methylations (HMTs), histone deacetylases (HDACs), histone demethylases (HDMs), ATP-dependent chromatin remodelers, and histone chaperones. The other complexes with presently unknown enzymatic activities are also assumed to be involved. Furthermore, these co-regulatory complexes are under the control of diverse extracellular and intracellular signaling pathways, which can sense changes in both the external environment and nutritional status, and direct appropriate transcriptional responses^[52].

4 Cofactors for ER and PR activation

Similar with the other transcription factors, both the ER and PR need to interact with the other proteins or cofactors in the nucleus to regulate the target gene expression. These cofactors could ensure the full activity of these hormone receptors through different mechanisms, such as mediating the epigenetic modification on target gene promoter which promotes the transcription, enhancing the binding of receptors to the responsive DNA element and regulating the level of active DNA bounded ER and PR.

4.1 SRCs

SRC/p160 family is a family of ligand-recruited co-activators of ER and PR. SRC/p160 family, the initially defined nuclear receptor co-activators, is structurally and functionally distinguishable from other molecules. A recurring structural feature of the co-activator proteins is a helical LXXLL motif, or nuclear receptor box^[53] presenting from a single to several copies in many co-activators, which is implicated in their ligand-dependent recruitment by the AF2-embedded

LBD domain of nuclear receptors. Moreover, several functional properties are common across different groups of co-activators. Acetyltransferase activity, for instance, with which co-activators are thought to target histones and other proteins to create a transcriptionally permissive environment at the promoter, is possessed by CBP^[54], P300/CBP-associated factor (PCAF)^[55], and members of the SRC family^[56,57].

SRC-1 is a widespread cofactor that can functionally interact with a wide variety of nuclear receptors and a plausible candidate for the biochemically-defined p160. However, the subsequent cloning of GRIP1/TIF2/SRC-2^[58] and p/CIP^[59] (also designated ACTR/RAC3/AIB-1/TRAM-1/SRC-3 herein) suggested that the term p160 encompasses a novel family of structurally-related nuclear receptor co-activators, the SRC-1 family. SRC-1, SRC-2/GRIP-1/TIF2 and p/CIP/SRC-3 exhibit common properties in the transcriptional activation of a wide variety of nuclear receptors^[60–62] (Table 1). This family has a number of structural features in common, and one of the most interesting is the presence of the PAS/bHLH domain in their N-termini. Members of the bHLH family are involved in regulation of cell differentiation and proliferation, and are characterized by the formation of homo or heterodimeric complexes with bHLH partners^[63]. Like other PAS-bHLH proteins^[64], SRC-1 and SRC-2 appear to be capable of forming multimeric complexes *in vivo*^[65], but the role of the PAS domain in this interaction is unclear. The phosphorylation-dependent multi-mono-ubiquitination event of SRC-3 also influenced its co-activational function with ER^[66].

4.2 CBP/P300

CBP/P300 plays a critical role in cell cycle regulation, cell differentiation and apoptosis and exhibits HAT activity^[67,68]. CBP/P300 also interacts with other HATs, such as PCAF^[55], and acetylates components of the basal transcription machinery. CBP/P300 are ubiquitous, evolutionarily conserved transcriptional co-activators for a host of diverse transcription factors, including CREB (cAMP-response element-binding protein)^[69], STAT-2^[70] and p53^[71,72]. Moreover, CBP has been shown to exist in a stably preformed complex with RNA Pol II^[73], suggesting that interaction of transcription factors with CBP, either directly or indirectly, might result in a direct link to basal transcription factors. It has been proposed that nuclear receptors might also require the mediation of CBP/P300 for efficient

Table 1. Phenotypes of ER, PR and cofactor mutant mice

Gene	Genotype	Phenotype	References
<i>Nr3c3 (Pgr)</i>	PRKO	Impaired implantation/decidualization/infertility	[168] [27]
	PR-AKO	Impaired implantation/decidualization/infertility	[27]
	PR-BKO	Normal implantation/decidualization	[27]
	PR ^{off}		
	Wnt7a-Cre	Impaired implantation/decidualization/infertility and the inability to cease estrogen-induced epithelial cell proliferation	[180]
<i>Nr3a1 (Esr1)</i>	ERαKO	Infertile/hypoplastic/no implantation/no decidual response persists with progesterone priming	[181]
<i>Nr3a2 (Esr2)</i>	ERβKO	Normal fertility uterine phenotype/exaggerated estrogen responsiveness	[182]
<i>Nr3a1 (Esr1)</i>	ERα ^{off}		
	Wnt7a-Cre	Infertile/Enhanced uterine apoptosis/Impaired decidualization due to control stromal proliferation and differentiation	[163, 183]
<i>Ube3a (E6AP)</i>	E6APKO	Reduced male reproductive function/female subfertility/mammary gland development defect	[94]
<i>Ncoa1</i>	SRC-1 ^{off} PR-Cre	Partial hormone resistance/impaired implantation/decidualization/ infertility	[184]
<i>Ncoa2</i>	SRC-2 ^{off} PR-Cre	Endometrial decidualization defect/impaired implantation/decidualization/ infertility	[185, 186]
<i>Ncoa3</i>	SRC-3 ^{off} PR-Cre	Female subfertility/mammary gland development defect	[187]
<i>Fkbp4</i>	Fkbp52KO	Implantation/decidualization defect/uterine progesterone resistance	[188–190]
<i>Ncor-6</i>	SRC-6 ^{off} PR-Cre	Implantation/decidualization defect/increased estrogen sensitivity causes infertility	[191]

transactivation^[74, 75]. It was shown that CBP, interacting weakly with nuclear receptors in a ligand-dependent manner, could enhance nuclear receptor-mediated transactivation, and was capable of binding to SRC-1 directly. CBP/P300 are proposed to be common integrators for distinct but convergent signaling pathways, functioning to integrate multiple different signals into an appropriate response at a common promoter^[75]. The role of CBP in steroid receptor signaling indicates that CBP and SRC-1 synergistically activate transcription from ER and PR regulated promoters^[76]. However biochemical analysis suggests that CBP and SRC-1 exist in largely distinct preformed complexes^[65], and it may be possible that they interact only transiently when recruited by ligand-bound receptors at the promoter.

4.3 Forkhead box protein A1 (FOXA1)

FOXA1 (also known as HNF3α), a member of the forkhead family of transcription factors, is expressed in many organs and plays a key role in development. FOXA proteins are the most studied pioneer transcription factors that bind to chromatin and enable the potential gene expressional activity. FOXA1 recruitment to chromatin is mediated by the epigenetic signature consisting of mono and di-methylated histone H3 on lysine 4 (H3K4me1/me2), which is a transcriptional

active mark^[77]. The pioneering properties of FOXA1 reside on its protein structure, which contains a winged helix domain that can structurally mimic linker histone, and thus permits its stable interaction with histone H3 and H4 with high affinity^[78, 79]. The high chromatin affinity of FOXA1 is a unique feature that allows it binding to the specific DNA sequences on the nucleosome core and displaces the linker histones, leading to de-compaction of chromatin and facilitating the binding by other transcription factors. In breast cancer cell lines that are hormone-sensitive and resistant, almost all ER-chromatin interactions and estrogen induced gene expression changes are dependent on the expression of FOXA1^[80]. Therefore, FOXA1 is a major determinant of ER activity in breast cancer.

4.4 GATA

The GATA family is composed of six highly conserved transcription factors (GATA-1 to GATA-6) identified in vertebrates, which bind to the DNA sequence (A/T)GATA (A/G) via two zinc-finger domains^[81]. In the breast, GATA-3 is expressed in luminal tumors^[82]. However, the mechanism of GATA-3 action or its potential role as a pioneer factor of ER and PR has not been described yet. Meanwhile, GATA-4 has been shown to have pioneering properties during early

development^[83] and for ER binding in U2OS osteosarcoma cell line^[84, 85], which stably expresses exogenous ER and very low levels of FOXA1^[80]. Interestingly, recent work has identified RunX1 as a mediator for ER-DNA interaction in MDA-MB-231 breast cancer cell line^[86] which stably expresses exogenous ER and is negative for the expression of FOXA1. These results support the idea that distinct pioneer proteins influence ER binding in FOXA1-negative tissues.

4.5 E6-associated protein (E6AP)

E6AP is a 100 kDa cellular protein that mediates the interaction of the human papilloma virus with p53. The association of p53 with E6AP promotes the specific ubiquitination and subsequent proteolytic degradation of p53 *in vitro*^[87, 88]. E6AP also functions as a ligand-activated co-activator for the steroid hormone receptors ER, AR, PR and growth hormone receptor (GHR)^[89–91]. It is co-recruited by ER/PR to promoters that contain an ERE/PRE^[92, 93]. A link between E6AP and ER/PR levels and/or activity has been genetically established: compared with wild-type littermates, E6AP-null animals show increased ER/PR protein levels in the mammary tissue but defective estrogen action (Table 1), aberrant ovulation, defective uterine growth and reduced fertility^[94]. By contrast, transgenic E6AP overexpression reduces ER levels in mouse mammary tissue^[90]. Src kinase accelerates estrogen dependent ER proteolysis^[95]. Estrogen/progesterone stimulates rapid Src kinase activation, and Src kinase phosphorylates ER/PR to facilitate their binding to E6AP. This complex is then recruited to a subset of ER/PR target gene promoters, leading to their transcriptional activation^[92]. The interaction between ER with E6AP also catalyzes rapid ER ubiquitylation in biochemical assays and in cells. Furthermore, the expression of a mutant (Y537F) ER results in increased ER stability but reduced binding to E6AP and reduced target gene activation^[92]. This study was the first to indicate that the crosstalk between ER and a specific kinase could mediate ER phosphorylation to promote the recruitment of a dual-role co-activator that also drives ER degradation^[92]. Although other studies have reported that ER Y537F is functional in ERE luciferase assays, such studies did not take into account the increased steady-state levels of ER Y537F when considering its transcriptional efficiency^[96, 97]. These data support a model in which ER transcriptional activation can be coupled to receptor degradation as a mechanism to fine-tune ER action. The possibility also

exists that Y537 phosphorylation could also modulate the interaction of ER with other ubiquitin ligase. These works suggests that receptor action and receptor levels are not synonymous. After ligand binding, ER transcriptional activity is maintained despite ongoing proteolysis and decreasing ER levels, introducing the possibility that hormonally sensitive tissues may not always have readily detectable levels of ER protein^[96, 97].

4.6 Murine double minute clone 2 (MDM2)

MDM2 was initially cloned from a transformed 3T3 cell line, which is a single-subunit RING finger E3 protein, identified as a p53-interacting protein^[98]. This multifunctional protein also promotes ER-mediated transcription and receptor proteolysis. Overexpression of MDM2 often occurs in breast cancer tissue and cell lines, but has not been shown to inversely correlate with ER levels. MDM2 functions as an ER co-activator^[99] and can directly interact with ER in a ternary complex with p53 to regulate ER turnover^[100]. Estrogen activates the cyclic co-recruitment of MDM2 and ER to the ERE motif of the target TFF1 promoter^[93]. MDM2 was recently shown to bind to ER and increase ER-Sp1-mediated transcriptional activation in MCF-7 and ZR-75 breast cancer cells^[98]. To date, the spectrum of ER target genes that are governed by the MDM2-ER interaction remains unknown. Furthermore, the relevance of this interaction to hormone-regulated cancers and its potential as a target for therapeutic intervention has not been explored.

4.7 Breast cancer 1 protein (BRCA1)

Germline mutations in BRCA1 predispose individuals to familial breast and ovarian cancers^[101], and BRCA1 is involved in DNA repair^[102]. BRCA1 binds to ER, and this complex has been postulated to have a role in DNA damage repair^[103, 104]. BRCA1 can function as a transcriptional regulator^[105], but it also binds to BARD1 to form a dimeric RING finger E3 ubiquitin ligase. Several lines of evidence suggest that BRCA1 functions as an E3 ligase for ER^[106, 107]. ER is an *in vitro* substrate for the BRCA1-BARD1 ubiquitin ligase, and cancer-predisposing BRCA1 mutations that affect the RING motif abrogate its *in vitro* E3 ligase function towards ER^[107, 108]. Although BRCA1-BARD1 can function as an E3 ligase *in vitro*, the effects of BRCA1 on ER transcriptional activity are controversial. It can both repress^[109] and activate ER-mediated transcription in different cellular contexts^[110]. BRCA1 can function as a co-repressor of ER-mediated transcription, but the

ectopic overexpression of either p300 or CBP reverses the inhibition of ER activity by BRCA1^[110]. Additional research has shown that estrogen-bound ER recruits BRCA1 into a transcriptional activation complex that contains the co-activator CBP^[111], but the subset of ER target genes that are co-regulated by BRCA1 has not been fully defined. BRCA1 appears to function as either a co-activator or a co-repressor of other steroid receptors in different cellular contexts^[112]. Most BRCA1-mutant breast cancers are ER negative^[113]. This has been postulated to result from transcriptional repression of *Esr1* by mutant BRCA1^[114], whereas wild-type BRCA1 activates *Esr1*. Interestingly, estrogen action appears to contribute to breast cancer development in *Brcal*-mutant carriers, since the risk of BRCA1-mutant breast cancer is decreased by prophylactic oophorectomy and by tamoxifen treatment^[113, 115, 116]. BRCA1 may serve a dual role as a co-activator and E3 ligase for ER to mediate constitutive estrogenic action, coupled to ER loss. This warrants further investigation since it would have substantial therapeutic implications.

5 Post-translational modifications of ER and PR upon activation

As the critical regulator for the reproductive process, both the ER and PR proteins were undergoing diverse modification responsive to many signaling transduction pathways in ligand-dependent and/or -independent manners. These covalent modification including phosphorylation, ubiquitination, methylation and other newly identified can influence the stability, subcellular localization, and/or affinity for the interact partners and many other activities, thus affecting these receptors' functions.

5.1 Ubiquitination

Ubiquitin is a small 76 amino-acid protein that can be reversibly attached to other proteins and lies at the core of an elaborate post-translational modification pathway. Ubiquitination of proteins is a sequential enzymatic cascade involving a ubiquitin activating enzyme (E1), a ubiquitin conjugating enzyme (E2) and a ubiquitin ligase (E3)^[117, 118].

Nuclear receptors are common targets of ubiquitination. The E2 enzymes UBCH5 and UBCH7 (also known as UBE2L3) have proven to be critical for ER/PR receptor-dependent transcriptional activities^[119]. PR

activities were stimulated by the yeast E3 ubiquitin ligase RSP5, as well as its human homologs hRPF1^[120] and E6AP^[89]. Co-expression of UBCH7 and E6AP enhance PR transcription synergistically, and SRC-1 functions as co-activator for PR also requires UBCH7^[121].

But the most common effect of PR poly-ubiquitination is ligand-dependent downregulation of nuclear receptor^[122]. In breast cancer cells, the half-life of unliganded PR is about 21 h, but falls to about 6 h after ligand binding^[123] due to their accelerated degradation by proteasomes^[124]. Thus, like other transcription factors, PR degradation is closely linked to high activity. Besides targeting the receptors, proteasomal degradation also influences multiple other factors critical to transcriptional activity including RNA polymerase II, which was recruited to receptor-bound promoters^[125].

Similarly, ER is rapidly ubiquitylated and degraded after estrogen binding^[126]. Ligand binding rapidly signals ER ubiquitylation and ubiquitylated ER cycles on and off ERE promoter sites to activate target gene transcription^[127]. Ubiquitin ligases MDM2^[100], SCF-SKP2^[128], and E6AP^[89] promote estrogen-induced transcriptional activity. A number of other CUL-RING ligases have also been shown to govern ER stability, such as CUL4B^[129], CUL5^[130], CUL7^[131]. In addition, some other ligases also function as steroid hormone receptor co-activators, such as ubiquitin-conjugating enzyme UBCH7^[121], thyroid hormone receptor-interacting protein 1 (TRIP1; also known as SUG1)^[132] and so on. After ligand binding, ER transcriptional activity is maintained despite ongoing proteolysis and decreasing ER levels, introducing the possibility that hormonally sensitive tissues may not always have readily detectable levels of ER protein^[133].

5.2 Sumoylation

Sumo proteins are about 10 kDa in size and resemble the three-dimensional structure of ubiquitin^[134], functioning as a reversible post-translational protein modifier^[135]. Unlike ubiquitin, sumoylation does not target proteins for degradation. Rather, sumoylation plays multiple roles in protein stabilization, subcellular localization, nuclear translocation, nuclear body formation and modulation (usually inhibition) of transcriptional activity^[136].

PR sumoylation has a suppressive effect on transcription^[137]. Sumoylated wild-type PRs have relatively low transcriptional activity compared to non-sumoylated mutants. Sumoylation of PR is especially important in

regulating activity of promoters with multiple PREs rather than promoters with a single PRE. PIAS1 functions as a sumo E3 ligase for PRs to inhibit their transcriptional activity and silencing of endogenous PIAS1 with siRNAs enhances the activity of wild-type PRs but has little effect on the activity of sumoylation-deficient PR mutants^[138]. UBC9, acting as the E2 enzyme in the sumoylation cascade, also acts as a co-regulator through recruitment of co-activators^[139].

5.3 Phosphorylation

Regulation of PR phosphorylation is complex in view of the multiple constitutive and ligand-stimulated sites^[140]. PR-B, the longest of the human PR isoforms, are 933 amino acids in length and contain at least 14 phosphorylation sites; mostly at serine (Ser, S) residues located in the N-terminus^[141]. Substitution of Ser294 in the amino-terminal domain by Ala decreases PR transcriptional activity by 50%–90% in a target gene specific manner^[142], increases protein stability^[143], and enhances PR sumoylation at K388^[144]. Interestingly, although this amino acid is common to both PR-B and PR-A, only the longer PR-B isoform is efficiently phosphorylated at this site^[145]. Phosphorylation of Ser345 promotes association of PR with Sp1 in target genes that lack canonical PREs^[146]; Ser81, 162, 190 and 400 are considered to be basal sites phosphorylated in the absence of hormones. Ser102, 294 and 345 are ligand-dependent sites phosphorylated 1–2 h after binding of hormones to the LBD^[147, 148]. Specific kinases responsible for phosphorylation of select sites have been identified but others remain unknown. Ligand-dependent kinases include CDK2, MAPK, PKA and PKC^[149, 150]. Functional roles for phospho-Ser345 and Ser400 have also been described. Ser345 for example, is phosphorylated by progestin-dependent rapid membrane signaling cascades that activate EGFR, c-Src and MAPK pathways and allow PR to target growth promoting genes that lack canonical PREs^[146]. Since the phosphorylation state of individual sites may control the transcription of only a subset of endogenous genes, under restricted physiological conditions and in tissue specific ways, discovering the true *in vivo* function of every post-translational modification on a site-by-site basis is a prodigious task.

The AF-2 domain on the C-terminal of ER is phosphorylated and thus activated by ligand binding of estrogen; meanwhile, the N-terminus AF-1 is activated by phosphorylation at several residues^[151]. Most

post-translational modifications occur in the N-terminus upon ligand binding, and ligand-independent growth factor signaling pathways^[152]. Substitution of Ser residues 104, 106 and 118 by Ala reduces transcriptional activity as measured by an ER responsive reporter^[153] and reduces co-activation of AF-1 by co-activators like p160 and CBP^[154]. Phosphorylation of the hinge site, Ser294, enhances ER activity measured by using a reporter^[155], and p38 MAPK-mediated phosphorylation of Ser294 stimulates ubiquitination and turnover of ER^[131]. Moreover, AKT-stimulated S167 phosphorylation can also mediate binding of ER with co-activator SRC-3 in the presence of estrogen; thus increasing ER transcription activity^[156, 157]. Concerning ER β in some contexts, Ser105Ala mutant shows reduced reporter activity relative to wild type form, and a Ser105Glu mutant exhibits enhanced reporter activity as well as the ability to reduce migration of breast cancer cells^[158]. Two serine residues of ER β phosphorylated by the MAPK pathway and leading to enhanced interaction with the co-activator SRC-1 in the absence of estrogen have been identified^[159]. Still, functional study of human ER β phosphorylation remains largely uncovered.

6 ER and PR in early pregnancy

6.1 ER in early pregnancy

The role of ERs was largely promoted by studies from the genetic mouse models. The ER α knockout (KO) mouse has a hypoplastic uterus and is infertile due to multiple defects including implantation failure^[160]. In contrast, the ER β KO mouse maintains normal implantation, further suggesting estrogen signals primarily via the ER α isoform in uterine function^[161] (Table 1). In the mouse, early uterine responses to estrogen include transcription of early cell cycle genes, hyperemia, infiltration of immune cells and water imbibition into the uterine tissue. Later responses include the further infiltration of immune cells, increased uterine weight and the induction of late cell cycle genes resulting in robust DNA synthesis and mitosis of epithelial cells^[162]. Consequently, uterine epithelium specific ER α KO displayed a significant increase in apoptosis. This evidence suggests the role of epithelial ER is to prevent epithelial apoptosis and ensuring a full epithelial response, while stromal ER is responsible for estrogen-driven epithelial proliferation^[163]. These observa-

tions are consistent with the tissue reconstitution studies and collectively illustrate the differential roles for ER during implantation. Prior to the implantation occurs, an estrogen surge on day 4 in mice was indispensable for the successful implantation, which was similarly observed in the human beings^[164]. Many studies have confirmed that the nidatory estrogen surge, mediated by ER, could induce glandular secretion of leukemia inhibitory factor (LIF), which is required to initiate the window of receptivity^[165]. LIF expression is also high in humans around the time of implantation^[164]. Clinical data has shown that endometria of women with unexplained infertility and multiple implantation failures often display significantly lower levels of LIF during the mid-secretory phase of their menstrual cycle when compared to healthy fertile controls^[166].

6.2 PR in early pregnancy

PR regulation of gene expression occurs by direct binding of the receptor in the regulatory promoter regions of target genes^[167], and PR binding ChIP-Seq datasets were overlapped with microarray gene expression comparing genes significantly induced by acute progesterone treatment. This analysis confirmed PR binding on both up-regulated (*Gata2*, *Egfr*, *Ihh*, *Fkbp5*, *Areg*, *Hand2*) and down-regulated (*Pgr*, *Wnt7a*, *Lifr*) progesterone target genes. Expression of both PR isoforms is observed in the murine uterus, and ablation of both isoforms (PR KO) results in multiple reproductive abnormalities, including a hyperplastic response to estrogen and an implantation defect^[168] (Table 1). However, specific ablation of PR-A (PR-A KO) and PR-B (PR-B KO) individually has shed light on the role of these isoforms in the mouse uterus. Ablation of PR-B resulted in no discernible uterine phenotype and displayed normal fertility. However, PR-B KO mice display reduced pregnancy-associated mammary gland morphogenesis, indicating PR-B is a major regulator of mammary gland maturation during pregnancy^[169]. Ablation of PR-A phenocopies the PR KO mouse uterine phenotype and indicates that the PR-A isoform is the predominant functional isoform in the mouse uterus^[27]. Collectively, these observations identify functional differences between these two isoforms in response to progesterone in the regulation of epithelial proliferation during early pregnancy. Vascular permeability is frequently associated with inflammation and triggered by a cohort of secreted permeability factors. Endothelial expressed PR

mediates local vascular permeability in response to progesterone, and it is demonstrated that PR activation of NR4A1 (Nur77/TR3) triggers barrier instability in the endothelium^[170]. In addition, aberrant activation of canonical Notch1 signaling in the mouse uterus decreases PR expression by promoter hypermethylation and leads to infertility^[171] and MicroRNA-200a serves a key role in the decline of PR function leading to term and preterm labor^[172].

The anti-proliferative action of progesterone in the endometrium has also been the focus of extensive research for its potential therapeutic role in regulating progression of estrogen-dependent pathologies; such as endometrial cancer and endometriosis^[173]. Contrasting mechanisms have been proposed for the progesterone-mediated inhibition of estrogen inducing epithelial cell proliferation. One line of evidence supports a paracrine mechanism while the alternative proposes a direct role of PR in the uterine epithelial cells. The paracrine mechanism for the inhibition of epithelial cell proliferation was strongly supported when the basic helix-loop-helix transcription factor Hand2 was shown to play an essential role in the regulation of growth factor signaling in a progesterone-dependent manner, conditional ablation of Hand2 using the PR^{cre/+}Hand2^{f/f} (Hand2^{d/d}) mouse model results in infertility due to an implantation defect and abnormal epithelium proliferation^[174]. Collectively these results identified a complicated mechanism of stromal-epithelial crosstalk regulating proliferation during implantation.

Therefore, PR downstream signaling is not only required for proper embryo attachment, but also is important in the support and development of the implanted embryo in decidualization. Besides the critical function of PR during the implantation, PR was also the key regulator for the stromal cell differentiation during the decidualization. Knockout mice have been pivotal in demonstrating that members of the bone morphogenetic protein (BMP) and wingless related MMTV integration site (Wnt) family are critical for these processes within early pregnancy under the control of PR signaling^[175]. Importantly, progesterone induces stromal cell decidualization in the late luteal phase and is essential for maintenance of the decidual phenotype in human^[176]. Moreover, loss of PR expression in decidual cells at term is thought to cause functional progesterone withdrawal that triggers inflammation at the maternal-fetal interface leading to

parturition^[177].

As discussed above, progesterone affects normal uterine function via a finely tuned and tissue/cell type specific balance between PR-A and PR-B mediated transcriptional activities. Most pathophysiological conditions of myometrium and endometrium are responsive to progesterone, albeit in an abnormal manner. PR-mediated progesterone actions vary according to the cell type.

7 Conclusions

This review illustrates the mechanisms of how ER and PR affect the expression of downstream genes. ER and PR both have the conservative structure of steroid receptors, including ligand-independent AF-1, DBD domain, LBD domain that contains a ligand-dependent AF-2. Possessing these special structure domains, ER and PR can play specific physiological functions in certain periods: mammogenesis, menstrual cycle, early pregnancy and so on. Activated ER and PR interact with various cofactors, not only widespread cofactors as SRCs, CBP/P300 and FOXA1, but also many ubiquitin ligases as E6AP, MDM2 and BRCA1 discovered in recent years. Additionally, post-translational modifications as mentioned ubiquitination, sumoylation and phosphorylation of ER and PR are essential for their activation. Recent advances have identified mechanisms that link the functions of ER and PR in early pregnancy.

As described above, *in vitro* analyses of the molecular biology of ER and PR have defined the mechanisms by which ER and PR regulate the transcription of specific target genes. Important to the understanding of the role of ER and PR in regulating uterine physiology is the identification of the specific target genes responding to hormones. Over the last decades, the mouse has emerged as a model system to investigate these hormone receptors in uterine biology *in vivo*. The mouse models will be used to better understand how the expression of the steroid hormone receptors is regulated in the uterus during pregnancy and the function of these receptors in regulating uterine biology.

Development of genetically engineered mouse models lacking ER, PR and their target genes has provided a wealth of information regarding the role of estrogen and progesterone regulated pathways in related diseases. ER and PR are widely distributed in various tissues and organs, especially in breast and uteri. Progesterone also

could induce adult mammary stem cell expansion (MaSCs) during the reproductive cycle, where MaSCs are putative targets for cell transformation events leading to breast cancer^[178,179]. There are many subtypes of breast cancer, existing as ER-positive and ER-negative ones. Researches on the structure and functional mechanisms of ER can be correlated with clinical outcomes. ER signaling and its crosstalk with various signaling pathways have been clinically associated with poor clinical outcomes and resistance to anti-estrogen therapies. Therefore, affecting either kinases or phosphatases regulating ER might help in treating patients with resistance to these therapies.

Future prospective clinical sequencing studies with large cohorts of tumors refractory to different hormonal therapies will clarify the association of the mutations with mechanisms of endocrine resistance. Specific inhibition of site modification on ER will offer new ideas for the treatment of ER positive breast cancers. As such, next-generation anti-estrogens are currently being tested in preclinical and clinical settings with promising results. In addition to anti-estrogens, further structure modeling studies will contribute to a better understanding of the conformation of ER and determine whether peptide derivatives can be tested as alternative targeted therapies.

Finally, given the crucial role of co-activators in the ligand-independent activation of the ER and PR, compounds that targeting co-activators may prove be effective strategy in reversing ER and PR mutant-driven endocrine resistance in many cancers and reproductive defects.

* * *

致谢: 本综述受国家自然科学基金项目(No. 81130009, 81330017, 81490744)资助。

REFERENCES

- 1 McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. *Cell* 2002; 108(4): 465–474.
- 2 Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. *Annu Rev Biochem* 1994; 63: 451–486.
- 3 Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? *Endocr Rev* 1999; 20(3): 358–417.
- 4 Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ,

- Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. *Pharmacol Rev* 2006; 58(4): 782–797.
- 5 Bain DL, Connaghan KD, Maluf NK, Yang Q, Miura MT, De Angelis RW, Degala GD, Lambert JR. Steroid receptor-DNA interactions: toward a quantitative connection between energetics and transcriptional regulation. *Nucleic Acids Res* 2014; 42(2): 691–700.
- 6 Nagy L, Schwabe JW. Mechanism of the nuclear receptor molecular switch. *Trends Biochem Sci* 2004; 29(6): 317–324.
- 7 Cato L, Neeb A, Brown M, Cato AC. Control of steroid receptor dynamics and function by genomic actions of the cochaperones p23 and Bag-1L. *Nucl Recept Signal* 2014; 12: e005.
- 8 Ismail A, Nawaz Z. Nuclear hormone receptor degradation and gene transcription: an update. *IUBMB Life* 2005; 57(7): 483–490.
- 9 Shemshedini L, Ji JW, Brou C, Chambon P, Gronemeyer H. In vitro activity of the transcription activation functions of the progesterone receptor. Evidence for intermediary factors. *J Biol Chem* 1992; 267(3): 1834–1839.
- 10 Faus H, Haendler B. Post-translational modifications of steroid receptors. *Biomed Pharmacother* 2006; 60(9): 520–528.
- 11 Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, Giguere V. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. *Mol Endocrinol* 1997; 11(3): 353–365.
- 12 White R, Lees JA, Needham M, Ham J, Parker M. Structural organization and expression of the mouse estrogen receptor. *Mol Endocrinol* 1987; 1(10): 735–744.
- 13 Walter P, Green S, Greene G, Krust A, Bornert JM, Jeltsch JM, Staub A, Jensen E, Scraze G, Waterfield M, et al. Cloning of the human estrogen receptor cDNA. *Proc Natl Acad Sci U S A* 1985; 82(23): 7889–7893.
- 14 Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, Chambon P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. *Nature* 1986; 320(6058): 134–139.
- 15 Menasce LP, White GR, Harrison CJ, Boyle JM. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. *Genomics* 1993; 17(1): 263–265.
- 16 Sluysers M, Rijkers AW, de Goeij CC, Parker M, Hilkens J. Assignment of estradiol receptor gene to mouse chromosome 10. *J Steroid Biochem* 1988; 31(5): 757–761.
- 17 Fasco MJ. Estrogen receptor mRNA splice variants produced from the distal and proximal promoter transcripts. *Mol Cell Endocrinol* 1998; 138(1–2): 51–59.
- 18 Grandien K, Berkenstam A, Gustafsson JA. The estrogen receptor gene: promoter organization and expression. *Int J Biochem Cell Biol* 1997; 29(12): 1343–1369.
- 19 Kuiper GG, Enmark E, Peltö-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. *Proc Natl Acad Sci U S A* 1996; 93(12): 5925–5930.
- 20 Bhat RA, Harnish DC, Stevis PE, Lyttle CR, Komm BS. A novel human estrogen receptor beta: identification and functional analysis of additional N-terminal amino acids. *J Steroid Biochem Mol Biol* 1998; 67(3): 233–240.
- 21 Thomas C, Gustafsson JA. Estrogen receptor mutations and functional consequences for breast cancer. *Trends Endocrinol Metab* 2015; 26(9): 467–476.
- 22 Leonhardt SA, Boonyaratanakornkit V, Edwards DP. Progesterone receptor transcription and non-transcription signaling mechanisms. *Steroids* 2003; 68(10–13): 761–770.
- 23 Li X, O'Malley BW. Unfolding the action of progesterone receptors. *J Biol Chem* 2003; 278(41): 39261–39264.
- 24 McDonnell DP. Unraveling the human progesterone receptor signal transduction pathway Insights into antiprogesterin action. *Trends Endocrinol Metab* 1995; 6(4): 133–138.
- 25 Hovland AR, Powell RL, Takimoto GS, Tung L, Horwitz KB. An N-terminal inhibitory function, IF, suppresses transcription by the A-isoform but not the B-isoform of human progesterone receptors. *J Biol Chem* 1998; 273(10): 5455–5460.
- 26 Kaya HS, Hantak AM, Stubbs LJ, Taylor RN, Bagchi IC, Bagchi MK. Roles of progesterone receptor A and B isoforms during human endometrial decidualization. *Mol Endocrinol* 2015; 29(6): 882–895.
- 27 Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. *Science* 2000; 289(5485): 1751–1754.
- 28 Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. *Mol Endocrinol* 1993; 7(10): 1244–1255.
- 29 Kraus WL, Weis KE, Katzenellenbogen BS. Determinants for the repression of estrogen receptor transcriptional activity by ligand-occupied progesterin receptors. *J Steroid Biochem Mol Biol* 1997; 63(4–6): 175–188.
- 30 Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. *Science* 1995; 270(5240): 1354–1357.

- 31 Chen D, Pace PE, Coombes RC, Ali S. Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. *Mol Cell Biol* 1999; 19(2): 1002–1015.
- 32 Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eickhout J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M. Genome-wide analysis of estrogen receptor binding sites. *Nat Genet* 2006; 38(11): 1289–1297.
- 33 Stossi F, Madak-Erdogan Z, Katzenellenbogen BS. Estrogen receptor alpha represses transcription of early target genes via p300 and CtBP1. *Mol Cell Biol* 2009; 29(7): 1749–1759.
- 34 Le Romancer M, Poulard C, Cohen P, Sentis S, Renoir JM, Corbo L. Cracking the estrogen receptor's posttranslational code in breast tumors. *Endocr Rev* 2011; 32(5): 597–622.
- 35 Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. *Endocr Rev* 1997; 18(3): 306–360.
- 36 Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. *Cell* 2003; 115(6): 751–763.
- 37 Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M, Gustafsson JA. Estrogen receptors: how do they signal and what are their targets. *Physiol Rev* 2007; 87(3): 905–931.
- 38 Guiochon-Mantel A, Delabre K, Lescop P, Milgrom E. The Ernst Schering Poster Award. Intracellular traffic of steroid hormone receptors. *J Steroid Biochem Mol Biol* 1996; 56(1–6 Spec No): 3–9.
- 39 Pratt WB, Silverstein AM, Galigniana MD. A model for the cytoplasmic trafficking of signalling proteins involving the hsp90-binding immunophilins and p50cdc37. *Cell Signal* 1999; 11(12): 839–851.
- 40 Wochnik GM, Ruegg J, Abel GA, Schmidt U, Holsboer F, Rein T. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. *J Biol Chem* 2005; 280(6): 4609–4616.
- 41 Davies TH, Ning YM, Sanchez ER. A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. *J Biol Chem* 2002; 277(7): 4597–4600.
- 42 Thackray VG, Toft DO, Nordeen SK. Novel activation step required for transcriptional competence of progesterone receptor on chromatin templates. *Mol Endocrinol* 2003; 17(12): 2543–2553.
- 43 McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. *Endocr Rev* 1999; 20(3): 321–344.
- 44 Gronemeyer H. Transcription activation by estrogen and progesterone receptors. *Annu Rev Genet* 1991; 25: 89–123.
- 45 Ham J, Thomson A, Needham M, Webb P, Parker M. Characterization of response elements for androgens, glucocorticoids and progestins in mouse mammary tumour virus. *Nucleic Acids Res* 1988; 16(12): 5263–5276.
- 46 Rubel CA, Lanz RB, Kommagani R, Franco HL, Lydon JP, DeMayo FJ. Research resource: Genome-wide profiling of progesterone receptor binding in the mouse uterus. *Mol Endocrinol* 2012; 26(8): 1428–1442.
- 47 Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. *Genes Dev* 2006; 20(11): 1405–1428.
- 48 O'Malley BW. Coregulators: from whence came these "master genes". *Mol Endocrinol* 2007; 21(5): 1009–1013.
- 49 Ito T, Bulger M, Pazin MJ, Kobayashi R, Kadonaga JT. ACF, an ISWI-containing and ATP-utilizing chromatin assembly and remodeling factor. *Cell* 1997; 90(1): 145–155.
- 50 Saha A, Wittmeyer J, Cairns BR. Chromatin remodelling: the industrial revolution of DNA around histones. *Nat Rev Mol Cell Biol* 2006; 7(6): 437–447.
- 51 Groth A, Rocha W, Verreault A, Almouzni G. Chromatin challenges during DNA replication and repair. *Cell* 2007; 128(4): 721–733.
- 52 Kato S, Yokoyama A, Fujiki R. Nuclear receptor coregulators merge transcriptional coregulation with epigenetic regulation. *Trends Biochem Sci* 2011; 36(5): 272–281.
- 53 Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. *Nature* 1997; 387(6634): 733–736.
- 54 Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. *Nature* 1996; 384(6610): 641–643.
- 55 Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. *Nature* 1996; 382(6589): 319–324.
- 56 Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. *Cell* 1997; 90(3): 569–580.
- 57 Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Steroid receptor coactivator-1 is a histone acetyltransferase. *Nature* 1997; 389(6647): 194–198.
- 58 Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-

- dependent activation function AF-2 of nuclear receptors. *EMBO J* 1996; 15(14): 3667–3675.
- 59 Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. *Nature* 1997; 387(6634): 677–684.
- 60 Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. *Proc Natl Acad Sci U S A* 1996; 93(10): 4948–4952.
- 61 Hong H, Kohli K, Garabedian MJ, Stallcup MR. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. *Mol Cell Biol* 1997; 17(5): 2735–2744.
- 62 Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. *Science* 1997; 277(5328): 965–968.
- 63 Hankinson O. The aryl hydrocarbon receptor complex. *Annu Rev Pharmacol Toxicol* 1995; 35: 307–340.
- 64 Pongratz I, Antonsson C, Whitelaw ML, Poellinger L. Role of the PAS domain in regulation of dimerization and DNA binding specificity of the dioxin receptor. *Mol Cell Biol* 1998; 18(7): 4079–4088.
- 65 McKenna NJ, Nawaz Z, Tsai SY, Tsai MJ, O'Malley BW. Distinct steady-state nuclear receptor coregulator complexes exist in vivo. *Proc Natl Acad Sci U S A* 1998; 95(20): 11697–11702.
- 66 Wu RC, Feng Q, Lonard DM, O'Malley BW. SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. *Cell* 2007; 129(6): 1125–1140.
- 67 Lonard DM, O'Malley B W. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. *Mol Cell* 2007; 27(5): 691–700.
- 68 Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. *Cell* 1996; 87(5): 953–959.
- 69 Kwok RP, Lundblad JR, Chrivia JC, Richards JP, Bachinger HP, Brennan RG, Roberts SG, Green MR, Goodman RH. Nuclear protein CBP is a coactivator for the transcription factor CREB. *Nature* 1994; 370(6486): 223–226.
- 70 Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D'Andrea A, Livingston DM. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. *Nature* 1996; 383(6598): 344–347.
- 71 Gu W, Shi XL, Roeder RG. Synergistic activation of transcription by CBP and p53. *Nature* 1997; 387(6635): 819–823.
- 72 Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. *Nature* 1997; 387(6635): 823–827.
- 73 Kee BL, Arias J, Montminy MR. Adaptor-mediated recruitment of RNA polymerase II to a signal-dependent activator. *J Biol Chem* 1996; 271(5): 2373–2375.
- 74 Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M, Evans RM. Role of CBP/P300 in nuclear receptor signalling. *Nature* 1996; 383(6595): 99–103.
- 75 Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Glass B, Lin SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. *Cell* 1996; 85(3): 403–414.
- 76 Smith CL, Onate SA, Tsai MJ, O'Malley BW. CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. *Proc Natl Acad Sci U S A* 1996; 93(17): 8884–8888.
- 77 Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS, Brown M. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. *Cell* 2008; 132(6): 958–970.
- 78 Kaestner KH, Knochel W, Martinez DE. Unified nomenclature for the winged helix/forkhead transcription factors. *Genes Dev* 2000; 14(2): 142–146.
- 79 Cirillo LA, McPherson CE, Bossard P, Stevens K, Cherian S, Shim EY, Clark KL, Burley SK, Zaret KS. Binding of the winged-helix transcription factor HNF3 to a linker histone site on the nucleosome. *EMBO J* 1998; 17(1): 244–254.
- 80 Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. *Nat Genet* 2011; 43(1): 27–33.
- 81 Kouros-Mehr H, Kim JW, Bechis SK, Werb Z. GATA-3 and the regulation of the mammary luminal cell fate. *Curr Opin Cell Biol* 2008; 20(2): 164–170.
- 82 Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A* 2001; 98(19): 10869–10874.
- 83 Bossard P, Zaret KS. GATA transcription factors as potentiators of gut endoderm differentiation. *Development* 1998; 125(24): 4909–4917.
- 84 Krum SA, Miranda-Carboni GA, Lupien M, Eeckhoute J, Carroll JS, Brown M. Unique ERalpha cistromes control cell type-specific gene regulation. *Mol Endocrinol* 2008; 22(11): 2393–2406.

- 85 Miranda-Carboni GA, Guemes M, Bailey S, Anaya E, CorSELLI M, Peault B, Krum SA. GATA4 regulates estrogen receptor-alpha-mediated osteoblast transcription. *Mol Endocrinol* 2011; 25(7): 1126–1136.
- 86 Stender JD, Kim K, Charn TH, Komm B, Chang KC, Kraus WL, Benner C, Glass CK, Katzenellenbogen BS. Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. *Mol Cell Biol* 2010; 30(16): 3943–3955.
- 87 Huibregtse JM, Scheffner M, Howley PM. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. *Mol Cell Biol* 1993; 13(8): 4918–4927.
- 88 Huibregtse JM, Scheffner M, Beaudenon S, Howley PM. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. *Proc Natl Acad Sci U S A* 1995; 92(7): 2563–2567.
- 89 Nawaz Z, Lonard DM, Smith CL, Lev-Lehman E, Tsai SY, Tsai MJ, O'Malley BW. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. *Mol Cell Biol* 1999; 19(2): 1182–1189.
- 90 Ramamoorthy S, Dhananjayan SC, Demayo FJ, Nawaz Z. Isoform-specific degradation of PR-B by E6-AP is critical for normal mammary gland development. *Mol Endocrinol* 2010; 24(11): 2099–2113.
- 91 Khan OY, Fu G, Ismail A, Srinivasan S, Cao X, Tu Y, Lu S, Nawaz Z. Multifunction steroid receptor coactivator, E6-associated protein, is involved in development of the prostate gland. *Mol Endocrinol* 2006; 20(3): 544–559.
- 92 Sun J, Zhou W, Kaliappan K, Nawaz Z, Slingerland JM. ERalpha phosphorylation at Y537 by Src triggers E6-AP-ERalpha binding, ERalpha ubiquitylation, promoter occupancy, and target gene expression. *Mol Endocrinol* 2012; 26(9): 1567–1577.
- 93 Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. *Mol Cell* 2003; 11(3): 695–707.
- 94 Smith CL, DeVera DG, Lamb DJ, Nawaz Z, Jiang YH, Beaudet AL, O'Malley BW. Genetic ablation of the steroid receptor coactivator-ubiquitin ligase, E6-AP, results in tissue-selective steroid hormone resistance and defects in reproduction. *Mol Cell Biol* 2002; 22(2): 525–535.
- 95 Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C, Chun K, Hennessy B, Mills GB, Nawaz Z, Slingerland JM. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. *J Clin Invest* 2007; 117(8): 2205–2215.
- 96 Yudit MR, Vorojeikina D, Zhong L, Skafar DF, Sasson S, Gasiewicz TA, Notides AC. Function of estrogen receptor tyrosine 537 in hormone binding, DNA binding, and transactivation. *Biochemistry* 1999; 38(43): 14146–14156.
- 97 Tremblay GB, Tremblay A, Labrie F, Giguere V. Ligand-independent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens. *Cancer Res* 1998; 58(5): 877–881.
- 98 Kim K, Burghardt R, Barhoumi R, Lee SO, Liu X, Safe S. MDM2 regulates estrogen receptor alpha and estrogen responsiveness in breast cancer cells. *J Mol Endocrinol* 2011; 46(2): 67–79.
- 99 Saji S, Okumura N, Eguchi H, Nakashima S, Suzuki A, Toi M, Nozawa Y, Saji S, Hayashi S. MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. *Biochem Biophys Res Commun* 2001; 281(1): 259–265.
- 100 Duong V, Boulle N, Daujat S, Chauvet J, Bonnet S, Neel H, Cavailles V. Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. *Cancer Res* 2007; 67(11): 5513–5521.
- 101 Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 1994; 266(5182): 66–71.
- 102 Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, Livingston DM. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. *Cell* 1997; 90(3): 425–435.
- 103 Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. *Oncogene* 2001; 20(1): 77–87.
- 104 Schultz-Norton JR, Ziegler YS, Nardulli AM. ERalpha-associated protein networks. *Trends Endocrinol Metab* 2011; 22(4): 124–129.
- 105 Deng CX, Brodie SG. Roles of BRCA1 and its interacting proteins. *Bioessays* 2000; 22(8): 728–737.
- 106 Dizin E, Irminger-Finger I. Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1. *Int J Biochem Cell Biol* 2010; 42(5): 693–700.
- 107 Eakin CM, Maccoss MJ, Finney GL, Kleivit RE. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase. *Proc Natl Acad Sci U S A* 2007; 104(14): 5794–5799.
- 108 Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H, Ohta T. The RING heterodimer

- BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. *J Biol Chem* 2001; 276(18): 14537–14540.
- 109 Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, Rosen EM. BRCA1 inhibition of estrogen receptor signaling in transfected cells. *Science* 1999; 284(5418): 1354–1356.
- 110 Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM. p300 Modulates the BRCA1 inhibition of estrogen receptor activity. *Cancer Res* 2002; 62(1): 141–151.
- 111 Crowe DL, Lee MK. New role for nuclear hormone receptors and coactivators in regulation of BRCA1-mediated DNA repair in breast cancer cell lines. *Breast Cancer Res* 2006; 8(1): R1.
- 112 Calvo V, Beato M. BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters. *Cancer Res* 2011; 71(9): 3422–3431.
- 113 Narod SA, Offit K. Prevention and management of hereditary breast cancer. *J Clin Oncol* 2005; 23(8): 1656–1663.
- 114 Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, James CR, Farragher SM, Mulligan JM, Scott AN, Dervan PA, Johnston PG, Couch FJ, Daly PA, Kay E, McCann A, Mullan PB, Harkin DP. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. *J Natl Cancer Inst* 2007; 99(22): 1683–1694.
- 115 Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med* 2002; 346(21): 1609–1615.
- 116 Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. *Eur J Cancer* 2002; 38 Suppl 6: S15–S17.
- 117 Ciechanover A. The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting. *Neurology* 2006; 66(2 Suppl 1): S7–S19.
- 118 Taylor N, Flemington E, Kolman JL, Baumann RP, Speck SH, Miller G. ZEBRA and a Fos-GCN4 chimeric protein differ in their DNA-binding specificities for sites in the Epstein-Barr virus BZLF1 promoter. *J Virol* 1991; 65(8): 4033–4041.
- 119 Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. *Cell* 2004; 116(4): 511–526.
- 120 Imhof MO, McDonnell DP. Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors. *Mol Cell Biol* 1996; 16(6): 2594–2605.
- 121 Verma S, Ismail A, Gao X, Fu G, Li X, O'Malley BW, Nawaz Z. The ubiquitin-conjugating enzyme UBCH7 acts as a coactivator for steroid hormone receptors. *Mol Cell Biol* 2004; 24(19): 8716–8726.
- 122 Wei LL, Krett NL, Francis MD, Gordon DF, Wood WM, O'Malley BW, Horwitz KB. Multiple human progesterone receptor messenger ribonucleic acids and their autoregulation by progestin agonists and antagonists in breast cancer cells. *Mol Endocrinol* 1988; 2(1): 62–72.
- 123 Nardulli AM, Greene GL, O'Malley BW, Katzenellenbogen BS. Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. *Endocrinology* 1988; 122(3): 935–944.
- 124 Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. *Trends Cell Biol* 1998; 8(10): 397–403.
- 125 Abdel-Hafiz HA, Horwitz KB. Post-translational modifications of the progesterone receptors. *J Steroid Biochem Mol Biol* 2014; 140: 80–89.
- 126 Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW. Proteasome-dependent degradation of the human estrogen receptor. *Proc Natl Acad Sci U S A* 1999; 96(5): 1858–1862.
- 127 Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. *Cell* 2000; 103(6): 843–852.
- 128 Zhou W, Srinivasan S, Nawaz Z, Slingerland JM. ERalpha, SKP2 and E2F-1 form a feed forward loop driving late ERalpha targets and G1 cell cycle progression. *Oncogene* 2014; 33(18): 2341–2353.
- 129 Ohtake F, Takeyama K, Matsumoto T, Kitagawa H, Yamamoto Y, Nohara K, Tohyama C, Krust A, Mimura J, Chambon P, Yanagisawa J, Fujii-Kuriyama Y, Kato S. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. *Nature* 2003; 423(6939): 545–550.
- 130 Johnson AE, Le IP, Buchwalter A, Burnatowska-Hledin MA. Estrogen-dependent growth and estrogen receptor (ER)-alpha concentration in T47D breast cancer cells are inhibited by VACM-1, a *cul 5* gene. *Mol Cell Biochem* 2007; 301(1–2): 13–20.
- 131 Bhatt S, Xiao Z, Meng Z, Katzenellenbogen BS. Phosphorylation by p38 mitogen-activated protein kinase promotes estrogen receptor alpha turnover and functional activity via the SCF(Skp2) proteasomal complex. *Mol Cell Biol* 2012; 32(10): 1928–1943.

- 132 Gottlicher M, Heck S, Doucas V, Wade E, Kullmann M, Cato AC, Evans RM, Herrlich P. Interaction of the Ubc9 human homologue with c-Jun and with the glucocorticoid receptor. *Steroids* 1996; 61(4): 257–262.
- 133 Zhou W, Slingerland JM. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. *Nat Rev Cancer* 2014; 14(1): 26–38.
- 134 Bernier-Villamor V, Sampson DA, Matunis MJ, Lima CD. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. *Cell* 2002; 108(3): 345–356.
- 135 Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. *Nat Rev Mol Cell Biol* 2007; 8(12): 947–956.
- 136 Gill G. SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? *Genes Dev* 2004; 18(17): 2046–2059.
- 137 Chauchereau A, Amazit L, Quesne M, Guiochon-Mantel A, Milgrom E. Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. *J Biol Chem* 2003; 278(14): 12335–12343.
- 138 Jones MC, Fusi L, Higham JH, Abdel-Hafiz H, Horwitz KB, Lam EW, Brosens JJ. Regulation of the SUMO pathway sensitizes differentiating human endometrial stromal cells to progesterone. *Proc Natl Acad Sci U S A* 2006; 103(44): 16272–16277.
- 139 Szapary D, Song LN, He Y, Simons SS, Jr. Differential modulation of glucocorticoid and progesterone receptor transactivation. *Mol Cell Endocrinol* 2008; 283(1–2): 114–126.
- 140 Lange CA. Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: who will have the last word? *Mol Endocrinol* 2004; 18(2): 269–278.
- 141 Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. *Steroids* 2011; 76(7): 636–652.
- 142 Shen T, Horwitz KB, Lange CA. Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. *Mol Cell Biol* 2001; 21(18): 6122–6131.
- 143 Lange CA, Shen T, Horwitz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. *Proc Natl Acad Sci U S A* 2000; 97(3): 1032–1037.
- 144 Daniel AR, Faivre EJ, Lange CA. Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. *Mol Endocrinol* 2007; 21(12): 2890–2906.
- 145 Clemm DL, Sherman L, Boonyaratanakornkit V, Schrader WT, Weigel NL, Edwards DP. Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. *Mol Endocrinol* 2000; 14(1): 52–65.
- 146 Faivre EJ, Daniel AR, Hillard CJ, Lange CA. Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. *Mol Endocrinol* 2008; 22(4): 823–837.
- 147 Weigel NL, Moore NL. Kinases and protein phosphorylation as regulators of steroid hormone action. *Nucl Recept Signal* 2007; 5: e005.
- 148 Pierson-Mullany LK, Lange CA. Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. *Mol Cell Biol* 2004; 24(24): 10542–10557.
- 149 Weigel NL, Zhang Y. Ligand-independent activation of steroid hormone receptors. *J Mol Med (Berl)* 1998; 76(7): 469–479.
- 150 Moore NL, Narayanan R, Weigel NL. Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity. *Steroids* 2007; 72(2): 202–209.
- 151 Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. *Cell* 1987; 51(6): 941–951.
- 152 Ward RD, Weigel NL. Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation. *Biofactors* 2009; 35(6): 528–536.
- 153 Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. *J Biol Chem* 1994; 269(6): 4458–4466.
- 154 Dutertre M, Smith CL. Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains. *Mol Endocrinol* 2003; 17(7): 1296–1314.
- 155 Williams CC, Basu A, El-Gharbawy A, Carrier LM, Smith CL, Rowan BG. Identification of four novel phosphorylation sites in estrogen receptor alpha: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2. *BMC Biochem* 2009; 10: 36.
- 156 Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. *Mol Endocrinol* 2006; 20(12): 3120–3132.

- 157 Chen D, Reierstad S, Lu M, Lin Z, Ishikawa H, Bulun SE. Regulation of breast cancer-associated aromatase promoters. *Cancer Lett* 2009; 273(1): 15–27.
- 158 Lam HM, Suresh Babu CV, Wang J, Yuan Y, Lam YW, Ho SM, Leung YK. Phosphorylation of human estrogen receptor-beta at serine 105 inhibits breast cancer cell migration and invasion. *Mol Cell Endocrinol* 2012; 358(1): 27–35.
- 159 Tremblay A, Tremblay GB, Labrie F, Giguere V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. *Mol Cell* 1999; 3(4): 513–519.
- 160 Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. *Proc Natl Acad Sci U S A* 1993; 90(23): 11162–11166.
- 161 Critchley HO, Brenner RM, Henderson TA, Williams K, Nayak NR, Slayden OD, Millar MR, Saunders PT. Estrogen receptor beta, but not estrogen receptor alpha, is present in the vascular endothelium of the human and nonhuman primate endometrium. *J Clin Endocrinol Metab* 2001; 86(3): 1370–1378.
- 162 Chen B, Pan H, Zhu L, Deng Y, Pollard JW. Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase-->AKT-->GSK-3beta-->cyclin D1-->pRB pathway to block uterine epithelial cell proliferation. *Mol Endocrinol* 2005; 19(8): 1978–1990.
- 163 Winuthayanon W, Hewitt SC, Orvis GD, Behringer RR, Korach KS. Uterine epithelial estrogen receptor alpha is dispensable for proliferation but essential for complete biological and biochemical responses. *Proc Natl Acad Sci U S A* 2010; 107(45): 19272–19277.
- 164 Dey SK, Lim H, Das SK, Reese J, Paria BC, Daikoku T, Wang H. Molecular cues to implantation. *Endocr Rev* 2004; 25(3): 341–373.
- 165 Chen JR, Cheng JG, Shatzer T, Sewell L, Hernandez L, Stewart CL. Leukemia inhibitory factor can substitute for nidatory estrogen and is essential to inducing a receptive uterus for implantation but is not essential for subsequent embryogenesis. *Endocrinology* 2000; 141(12): 4365–4372.
- 166 Wu M, Yin Y, Zhao M, Hu L, Chen Q. The low expression of leukemia inhibitory factor in endometrium: possible relevant to unexplained infertility with multiple implantation failures. *Cytokine* 2013; 62(2): 334–339.
- 167 Jacobsen BM, Horwitz KB. Progesterone receptors, their isoforms and progesterone regulated transcription. *Mol Cell Endocrinol* 2012; 357(1–2): 18–29.
- 168 Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA, Jr., Shyamala G, Conneely OM, O'Malley BW. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. *Genes Dev* 1995; 9(18): 2266–2278.
- 169 Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. *Proc Natl Acad Sci U S A* 2003; 100(17): 9744–9749.
- 170 Goddard LM, Murphy TJ, Org T, Enciso JM, Hashimoto-Partyka MK, Warren CM, Domigan CK, McDonald AI, He H, Sanchez LA, Allen NC, Orsenigo F, Chao LC, Dejana E, Tontonoz P, Mikkola HK, Iruela-Arispe ML. Progesterone receptor in the vascular endothelium triggers physiological uterine permeability preimplantation. *Cell*; 156(3): 549–562.
- 171 Su RW, Strug MR, Jeong JW, Miele L, Fazleabas AT. Aberrant activation of canonical Notch1 signaling in the mouse uterus decreases progesterone receptor by hypermethylation and leads to infertility. *Proc Natl Acad Sci U S A* 2016; 113(8): 2300–2305.
- 172 Williams KC, Renthall NE, Condon JC, Gerard RD, Mendelson CR. MicroRNA-200a serves a key role in the decline of progesterone receptor function leading to term and preterm labor. *Proc Natl Acad Sci U S A* 2012; 109(19): 7529–7534.
- 173 Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. *Endocr Rev* 2013; 34(1): 130–162.
- 174 Li Q, Kannan A, DeMayo FJ, Lydon JP, Cooke PS, Yamagishi H, Srivastava D, Bagchi MK, Bagchi IC. The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2. *Science* 2011; 331(6019): 912–916.
- 175 Wetendorf M, DeMayo FJ. The progesterone receptor regulates implantation, decidualization, and glandular development via a complex paracrine signaling network. *Mol Cell Endocrinol* 2012; 357(1–2): 108–118.
- 176 Das A, Mantena SR, Kannan A, Evans DB, Bagchi MK, Bagchi IC. De novo synthesis of estrogen in pregnant uterus is critical for stromal decidualization and angiogenesis. *Proc Natl Acad Sci U S A* 2009; 106(30): 12542–12547.
- 177 Lockwood CJ, Stocco C, Murk W, Kayisli UA, Funai EF, Schatz F. Human labor is associated with reduced decidual cell expression of progesterone, but not glucocorticoid, receptors. *J Clin Endocrinol Metab* 2010; 95(5): 2271–2275.
- 178 Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R. Progesterone induces adult mammary stem cell expansion. *Nature* 2010; 465(7299): 803–807.
- 179 Brisken C. Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. *Nat Rev Cancer* 2013; 13(6): 385–396.

- 180 Franco HL, Rubel CA, Large MJ, Wetendorf M, Fernandez-Valdivia R, Jeong JW, Spencer TE, Behringer RR, Lydon JP, Demayo FJ. Epithelial progesterone receptor exhibits pleiotropic roles in uterine development and function. *FASEB J* 2012; 26(3): 1218–1227.
- 181 Greco TL, Duello TM, Gorski J. Estrogen receptors, estradiol, and diethylstilbestrol in early development: the mouse as a model for the study of estrogen receptors and estrogen sensitivity in embryonic development of male and female reproductive tracts. *Endocr Rev* 1993; 14(1): 59–71.
- 182 Cooke PS, Buchanan DL, Young P, Setiawan T, Brody J, Korach KS, Taylor J, Lubahn DB, Cunha GR. Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. *Proc Natl Acad Sci U S A* 1997; 94(12): 6535–6540.
- 183 Pawar S, Laws MJ, Bagchi IC, Bagchi MK. Uterine epithelial estrogen receptor- α controls decidualization via a paracrine mechanism. *Mol Endocrinol* 2015; 29(9): 1362–1374.
- 184 Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ, O'Malley BW. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. *Science* 1998; 279(5358): 1922–1925.
- 185 Jeong JW, Lee KY, Han SJ, Aronow BJ, Lydon JP, O'Malley BW, DeMayo FJ. The p160 steroid receptor coactivator 2, SRC-2, regulates murine endometrial function and regulates progesterone-independent and -dependent gene expression. *Endocrinology* 2007; 148(9): 4238–4250.
- 186 Gehin M, Mark M, Dennefeld C, Dierich A, Gronemeyer H, Chambon P. The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. *Mol Cell Biol* 2002; 22(16): 5923–5937.
- 187 Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, O'Malley BW. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. *Proc Natl Acad Sci U S A* 2000; 97(12): 6379–6384.
- 188 Tranguch S, Wang H, Daikoku T, Xie H, Smith DF, Dey SK. FKBP52 deficiency-conferred uterine progesterone resistance is genetic background and pregnancy stage specific. *J Clin Invest* 2007; 117(7): 1824–1834.
- 189 Tranguch S, Cheung-Flynn J, Daikoku T, Prapapanich V, Cox MB, Xie H, Wang H, Das SK, Smith DF, Dey SK. Cochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation. *Proc Natl Acad Sci U S A* 2005; 102(40): 14326–14331.
- 190 Yang Z, Wolf IM, Chen H, Periyasamy S, Chen Z, Yong W, Shi S, Zhao W, Xu J, Srivastava A, Sanchez ER, Shou W. FK506-binding protein 52 is essential to uterine reproductive physiology controlled by the progesterone receptor A isoform. *Mol Endocrinol* 2006; 20(11): 2682–2694.
- 191 Kawagoe J, Li Q, Mussi P, Liao L, Lydon JP, DeMayo FJ, Xu J. Nuclear receptor coactivator-6 attenuates uterine estrogen sensitivity to permit embryo implantation. *Dev Cell* 2012; 23(4): 858–865.